secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-10-19T23:59:59+00:00
Accession:  0001387131-23-012417
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 5.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DMK Pharma appoints new CFO and General Counsel amid Nasdaq delisting risk
--------------------------------------------------------------------------

- Appointed Seth Cohen as CFO (base salary $400k) and John Dorbin as General Counsel (base salary $230k).
- Nasdaq issued superseding notice: Company not eligible for 180-day grace period on bid price rule due to prior monitor status.
- Hearing scheduled to address bid price and MVLS non-compliance; delisting possible if extension not granted.
- Cohen receives inducement option for 151,416 shares at $0.6016; Dorbin recommended for 70,000 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/0001387131-23-012417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713123012417/dmk-8k_101623.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-012417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer